...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer Cell >ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.
【24h】

ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

机译：ERBB受体：从致癌基因发现到基础科学再到基于机制的癌症疗法。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

ERBB receptors were linked to human cancer pathogenesis approximately three decades ago. Biomedical investigators have since developed substantial understanding of the biology underlying the dependence of cancers on aberrant ERBB receptor signaling. An array of cancer-associated genetic alterations in ERBB receptors has also been identified. These findings have led to the discovery and development of mechanism-based therapies targeting ERBB receptors that have improved outcome for many cancer patients. In this Perspective, we discuss current paradigms of targeting ERBB receptors with cancer therapeutics and our understanding of mechanisms of action and resistance to these drugs. As current strategies still have limitations, we also discuss challenges and opportunities that lie ahead as basic scientists and clinical investigators work toward more breakthroughs.
机译：大约三十年前，ERBB受体与人类癌症的发病机理有关。此后，生物医学研究者对癌症依赖异常ERBB受体信号转导的生物学基础有了深入的了解。 ERBB受体中一系列与癌症相关的遗传改变也已被鉴定。这些发现导致针对ERBB受体的基于机制的疗法的发现和发展，该疗法已改善了许多癌症患者的预后。在此观点中，我们讨论了以癌症治疗剂靶向ERBB受体的当前范例，以及我们对这些药物的作用机理和耐药性的理解。由于当前的策略仍然有局限性，我们还将讨论基础科学家和临床研究人员朝着更大的突破努力时所面临的挑战和机遇。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号